---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-199416"
form_type: "8-K"
ticker: "XOMA"
cik: "0000791908"
company_name: "XOMA Royalty Corp"
filed_at: "2024-08-13T23:59:59+00:00"
generated_at: "2026-05-31T09:54:55.849818+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# XOMA Royalty Q2 net income $16.0M; receives $22.6M cash; acquires Kinnate and Daré rights; posts $9.0M impairment

## Summary
- Net income $16.0M vs net loss $5.4M in Q2 2023; total income/revenue $11.1M; cash receipts $22.6M.
- Completed acquisition of Kinnate Pharmaceuticals, adding >$9.5M cash and potential royalty streams; acquired Daré's XACIATO, Ovaprene, Sildenafil Cream rights.
- Recorded $9.0M non-cash impairment on Aronora programs; $19.3M gain on Kinnate acquisition, partially offset by $8.1M derivative charge.
- Zevra's arimoclomol received favorable advisory committee vote; FDA PDUFA date Sept 21, 2024.

## SEC filing metadata
- accession: 0001193125-24-199416
- form_type: 8-K
- ticker: XOMA
- cik: 0000791908
- company_name: XOMA Royalty Corp
- filed_at: 2024-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/791908/000119312524199416/0001193125-24-199416-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/791908/000119312524199416/d829744d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-199416
- JSON: https://secwatch.observer/filing/0001193125-24-199416.json
- Plain text: https://secwatch.observer/filing/0001193125-24-199416.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.